OP-2024-001 Study

The Comparative Pharmacokinetic Study of OP-2024 in Healthy Male Volunteers

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2071210039

Enrollment

Registered

2021-06-30

Start date

2021-07-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Oral administration of OP-2024 (1 capsule) or control (1 tablet).

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Healthy Japanese male. 2) Those with age >= 20 to = 18.5 to < 25.0. 4) Those who have provided voluntary written consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1) Those with a history of allergies to investigational drug ingredients, drugs, or foods 2) Those who are undergoing treatment for, or have a history of, respiratory, circulatory, central nervous system, gastrointestinal, hepatic, renal, hematopoietic, or endocrine disorders that affect pharmacokinetics 3) Other protocol defined exclusion criteria could apply

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics	—

Secondary

Measure	Time frame
Safety	—

Contacts

Public ContactDepartment of Clinical Development

OHARA Pharmaceutical Co.,Ltd.

chiken@ohara-ch.co.jp+81-3-6740-7701

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026